merwento

Dr Merve Özkan, # medicaloncologist MD

[merwento @picwikian]

Regorafenib therapy as a third-line treatment for... : Medicine https://t.co/h4R8YkVmym

[merwento @picwikian]

@caliraf @HendriksLizza
#oncology #thoraciconcology #akciğerkanseri

Another excellent presentation and a highly valuable discussion, offering great insights into the latest developments.

[merwento @picwikian]

@HendriksLizza Thank you for the insightful presentation. Great to stay up to date! 🙏

[Paolo Tarantino @PTarantinoMD]

BREAKING: SERENA-4 is negative. Similar to giredestrant, camizestrant did not improve outcomes vs AI when combined to CDK4/6i in the 1L setting. Its role remains confined to pts with ESR1 mutations, which seems to be the sweet spot for oral SERDs in MBC. https://t.co/d4g58bmmzM

[merwento @picwikian]

It's great to be part of a clinical research course with inspiring presentations @ASCO @onkolojidernegi

[Linda Martin @LindaMThoracic]

Can’t wait for MDT-Bridge results to be public! @DoctorJSpicer @MartinReck2 @Oncology_at_AZ @tssmn #lcsm @GenThorSurgClub @STS_CTsurgery @AATSHQ @UVASurgery @UVACancerCenter

[Paolo Tarantino @PTarantinoMD]

One week to #ESMO25. An unprecedented ESMO conference. Seven positive press releases, anticipating the expansion of T-DXd to the curative setting, two Trop2 ADCs reaching first-line mTNBC, 2 novel ET-based combos, adjuvant CDK4/6i improving OS. See you in Berlin! #ESMOAmbassadors

[Zach Klaassen @zklaassen_md]

The honesty, thoughtfulness, and wit of @ChrisSweens1

Phase 3 trials of Immunotherapy in Prostate Cancer --
A Case Study of "Failed All-Comer Strategy"

⚡️8 negative trials
💰 >$700 million USD
👨‍🦰 7,305 patients

#ESMO24 @urotoday

[Paolo Tarantino @PTarantinoMD]

Ribociclib is now approved by the FDA for the adjuvant treatment of patients with stage II and III ER+/HER2- breast cancer based on the NATALEE trial, showing 5% iDFS benefit at 4 years with the addition of ribo to adjuvant endocrine treatment

[Myriam Chalabi @MyriamChalabi]

Incredibly proud of Peter de Gooyer from my group presenting NICHE-3 on neoadj nivo/rela in dMMR colon cancer at #ESMO24 with concomitant publication in @NatureMedicine ➡️ open access https://t.co/rditsr605Q @NKI_nl #ESMOAmbassadors

[Yakup Ergün @dr_yakupergun]

#ESMO24
Stage-Matched Therapeutic Strategies for Thymic Epithelial Tumours
(@myESMO pocket guideline)

[Oncology Brothers @OncBrothers]

#Ribociclib now @US_FDA ✅ for adj early stage HR+ breast cancer. Recent #ESMO24 #NATALEE: Stg IIA - III, 400mg (3wks on/1wk off) for 3yrs

- Improved iDFS w/Ribo at 4yrs (HR: 0.715)
- Improvement seen in all subgroups including N0. OS immature

#bcsm #OncTwitter @OncoAlert

[Nirmal Raut @oncologician]

#ESMO2024 Total neoadjuvant treatment (TNT) with non-operative management (NOM) for proficient mismatch repair locally advanced rectal cancer (pMMR LARC): First results of NO-CUT trial by Alessio Amatu
- 97% dfs , 85% organ preservation achieved

[merwento @picwikian]

@myESMO @yusufdikec

[Tom Powles @tompowles1]

Presidential for @Silke_Gillessen @Uromigos #ESMO2024 Radium223 + enza vs enza alone shows a PFS and OS advantage in metastatic CRPC. PEACE3 is an investigator trial and rejuvenates radium-223 in prostate cancer. 0.69 HR for PFS and OS !!!

[Tom Powles @tompowles1]

The 1st disitimab Vedotin (HER-2 MMAE ADC) & pembro showing 1st line response rates of 75% in HER 1-3+ UC. Toxicity profile looks distinct from EV (fatigue>skin). There is a global randomised phase 3 of DV & pembro vs standard chemotherapy. #ESMO24
@DrRosenbergMSK @MattGalsky

[Tom Powles @tompowles1]

Nectin-4 is the target for Enfortumab Vedotin and is widely expressed in UC (median 275/300) . EV302 is 1st randomised trial to explore its relationship with response. IHC results show no clear relationship between Nectin-4 and outcome (RR,PFS,OS) or PD-L1 #ESMO2024

[Myriam Chalabi @MyriamChalabi]

Two years later, on Sept 15th #ESMO24, I will present the long awaited 3-year DFS data for NICHE-2 ‼️
But that’s not all…exciting🩸ctDNA dynamics included. See you there! @myESMO @NKI_nl

[〽️akido @BasaranSeckin]

Sana helal olsun👊 sen bu olimpiyatın Kadın Şampiyonusun. Erkekler devam edebilirler... #BusenazSürmeneli

[merwento @picwikian]

@DrYukselUrun Great ))))